Compares two moisturizers for skin care in adults with atopic dermatitis
Tests a moisturizing cream against another cream in adults with mild to moderate eczema.
Plain-language title generated from the registry record
Registry title: CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
Key facts
- Where
- Roma, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07204561, who can take part
Where in Italy
- Fondazione PTV - POLICLINICO TOR VERGATARoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
- Trial code
- NCT07204561
- Record updated
- 2 October 2025
- Original description
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.Read full original descriptionShow less
Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.
Inclusion: Subjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score; Participants of any gender, aged 18 years or over, from any phototype or ethnic group; Participants must be willing and able to give informed consent to participate in the study.
Exclusion: Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors; Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD); Age <18 years. Participants who are unwilling or unable to give informed consent to participate in the study.